In vivo CAR T-cell therapy could revolutionize cancer treatment by bypassing traditional manufacturing, reducing costs, and minimizing adverse events. Kelonia Therapeutics' KLN-1010 has shown ...
In a sign of changing times, AT&T, the nation's largest wireless provider, will be switching from traditional landlines in favor of a more modern option. Customers have received letters explaining the ...
The deadline to file a claim for money from the $177 million AT&T class action settlement is coming up. AT&T agreed to the settlement to resolve a lawsuit that accused it of failing to protect ...
The first time Chris Dahl heard rumblings of a plan to build a large solar array among the corn fields and tobacco sheds of East Windsor, she said the project sounded like a good enough idea. A ...
The selloff in Array Digital Infrastructure's fixed-income securities post-UScellular sale is overdone, creating an attractive entry point. AD's 5.50% Senior Notes now yield 8.05% and trade at a 31.6% ...
Gilead Sciences has become the latest pharma to strengthen its in vivo cell therapy credentials this year, paying $350 million for CAR-T developer Interius BioTherapeutics. Integrating Interius into ...
After suffering two significant data breaches in recent years, AT&T has agreed to pay $177 million to customers affected by the incidents. Some individuals could receive as much as $5,000 as part of ...
BELLEVUE, Wash.--(BUSINESS WIRE)--T-Mobile US, Inc. (NASDAQ: TMUS) (the “Company”) today announced, together with T-Mobile USA, Inc., its wholly-owned subsidiary (“T-Mobile USA”), the expiration and ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A Chicago-based wireless company ...
AbbVie is making a full strength play for the in vivo CAR-T market, snapping up Capstan Therapeutics for $2.1 billion to add an early-phase autoimmune drug candidate to its pipeline. Capstan is part ...
Capstan Therapeutics scientists demonstrate that lipid nanoparticles can engineer CAR T cells within the body without laboratory cell manufacturing and ex vivo expansion. The method using targeted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback